Why the study?
Although stereotactic body radiation therapy shows promise for refractory ventricular arrhythmias in short-term reports, randomized data, long-term outcomes, and mechanisms of action remain unknown.
Does stereotactic body radiation therapy (SBRT) reduce ventricular arrhythmias in patients with refractory ventricular arrhythmias?
Does stereotactic body radiation therapy (SBRT) reduce ventricular arrhythmias in patients with refractory ventricular arrhythmias?
SBRT is a promising non-invasive therapy for refractory ventricular arrhythmias, but randomized clinical trials are needed to address outstanding questions regarding mechanism, long-term safety, and efficacy.
First RCT of SBRT for ventricular arrhythmias; extends case series to randomized long-term efficacy and safety data.
Stereotactic body radiation therapy (SBRT) is a promising new method for non-invasive management of life-threatening ventricular arrhythmias. Numerous case reports and case series have provided encouraging short-term results suggesting good efficacy and safety, but randomized data and long-term outcomes are not yet available. The primary hypothesis as to the mechanism of action for SBRT relates to the development of cardiac fibrosis in arrhythmogenic myocardial substrate; however, limited animal model data offer conflicting insights into this theory. The use of SBRT for patients with refractory ventricular arrhythmias is rapidly increasing, but ongoing translational science work and randomized clinical trials will be critical to address many outstanding questions regarding this novel therapy.
No takes yet. Share an insight, caveat, or question.
Hayase et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: